First Department

NEW YORK CITY ORGANIZATION OF PUBLIC SERVICE RETIREES SECURES ANOTHER APPELLATE VICTORY FOR RETIREE HEALTHCARE RIGHTS

Retrieved on: 
Friday, May 26, 2023
First Department, Elderly care, New York State Supreme Court, Appellate Division, First Department, Organization, Pension, EmblemHealth, Multimedia, New York Supreme Court, Milk, Medicare, MLC, City, Supreme court, Court, PBA, Health, Book, Health insurance

The First Department held that the retirees "established a likelihood of success on the merits" of their lawsuit. It also held that the retirees had demonstrated that they "would suffer irreparable harm -- delaying or foregoing medical care, and inability to pay certain expenses, including necessities such as utilities -- if they were required to continue paying the co-payments."

Key Points: 
  • NEW YORK, May 26, 2023 /PRNewswire/ -- The NYC Organization of Public Service Retirees secured another major appellate victory on behalf of Medicare-eligible retired City workers and their dependents.
  • In response, Marianne Pizzitola, President of the New York City Organization of Public Service Retirees, issued the following statement: "Once again, six out of six Supreme Court justices have concluded that the City violated retirees' rights and inflicted irreparable harm on them.
  • If the Mayor and the MLC insist on continuing to violate retirees' healthcare rights, we will continue to take them to court.
  • The New York City Organization of Public Services Retirees are jointly represented by Jacob Gardener of Walden Macht & Haran and Steve Cohen, Sara Mark, Max Rodriguez of Pollock Cohen LLP.

Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19

Retrieved on: 
Thursday, May 11, 2023
Science, Research, Pharmaceutical, Health, COVID-19, University, Education, Clinical Trials, Vaccine, First Department, Smell, Kirin Holdings, Food, Anosmia, Rotavirus, Shortness, Headache, SARS-CoV-2, PDC, Consumer Affairs Agency, Clinical trial, Infection, Division, Multimedia, Chest pain, Fatigue, Lactococcus lactis, Pandemic, Patient, Patent, Risk, Fever Dream, Immune system, Internal medicine, Randomized controlled trial, Blood, Viral load, Shortness of breath, Nagasaki University, Cough, Respiratory Medicine, Institute for Plasma Research, Safety, Pharmaceutical industry, Copper, Omicron, Kirin, Anorexia nervosa, Dysgeusia, Limited, Immunity, Lactococcus, Plasma

Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.

Key Points: 
  • Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.
  • lactis strain Plasma*1 (L.lactis Plasma, a postbiotic), researched and developed by Kirin Holdings Company, Limited (Kirin Holdings).
  • Nagasaki University and Kirin Holdings have jointly filed a patent application for the findings of this specified clinical trial.
  • Nagasaki University and Kirin hope that L. lactis Plasma will become one of the new treatment or adjunctive care to patients with mild COVID-19.

Fox Corporation (FOX, FOXA) Shareholder Alert: Robbins LLP Informs Shareholders it is Investigating Fox Corporation on Behalf of Shareholders

Retrieved on: 
Wednesday, February 15, 2023
Steps, Fox Corporation, Fox, Defamation, Appellate Division, First Department, Fox News, New York State Supreme Court, Appellate Division, First Department, News, FOXA, Dominion Voting Systems, Delaware Superior Court, Murdoch family, SAN, FOX, Trump, Smartmatic, Dominion

If you would like more information about our investigation of Fox Corporation's misconduct, click here .

Key Points: 
  • If you would like more information about our investigation of Fox Corporation's misconduct, click here .
  • What is this Case About: Fox Corporation and Fox News, among others, are Being Sued for Defamation
    In November and December of 2020, Fox News broadcasted reports stating that the U.S. election was rigged.
  • Fox News specifically called out Smartmatic and Dominion Voting Systems, voting technology and software companies, for their alleged involvement in rigging the election.
  • Next Steps: If you own shares of Fox Corporation (FOX, FOXA), you have legal options.

DGAP-News: Lisen Imprinting Diagnostics Announces a Revolutionary Early Diagnostic Method for Lung Cancer

Retrieved on: 
Monday, December 20, 2021
Medical school, Shanghai Chest Hospital, Degenerative disease, Fudan University, Cancer, Diagnosis, Lung cancer, Allele, Biomarker, Critical Care Medicine (journal), Breast, First Department, Survival, Institute, Lung, Prostate, Johns Hopkins University, CEO, Research, Gene, Neoplasm, Patient, Mortality, Paper, Respiratory Medicine, Department, R, Carcinoma, Ohio State University, Second Affiliated Hospital of Xinjiang Medical University, PA, Impact, Technology, Medical imaging, Southeast University, Lisen Imprinting Diagnostics, Inc., Imprinted Genes, LISEN IMPRINTING DIAGNOSTICS, INC., IMPRINTED GENES

WUXI, CHINA & PHILADELPHIA, PA / ACCESSWIRE / December 15, 2021 / Lisen Imprinting Diagnostics ("LisenID" or "the company") announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection.

Key Points: 
  • WUXI, CHINA & PHILADELPHIA, PA / ACCESSWIRE / December 15, 2021 / Lisen Imprinting Diagnostics ("LisenID" or "the company") announces an innovative and ground-breaking epigenetics-based diagnostic solution for early lung cancer detection.
  • The present study particularly focused on lung cancer, which has the highest reported mortality among all cancers.
  • This method could greatly improve the diagnostic performance of preoperative cytopathology, promote the early diagnosis and treatment of lung cancer, and increase the survival of lung cancer patients.
  • During preoperative detection, the diagnostic model can accurately distinguish benign lung diseases from lung cancer demonstrating far superior diagnostic sensitivity than cytopathology, particularly for early lung cancer and small lung nodules.

ACP Private Equity Fund to Appeal Decision to the New York Court of Appeals in Dispute with New York Attorney General

Retrieved on: 
Wednesday, October 27, 2021
New, First Department, Homelessness, NYAG, Foundation, Worldvision Enterprises, University, JPMorgan Chase, Laurence Allen, Financial Industry Regulatory Authority, Appellate Division, Internal Revenue Code, MBA, General counsel, Constitution, Security (finance), UBS, Poverty, Bear Stearns, AG, Warwick Investment Group, SEC, Cryptocurrency, FINRA, Risk, SPIC, Morgan Stanley, Police Athletic League of New York City, LLC, Investment, Organic, Merrill (company), Bowery Mission, New York Supreme Court, Appellate Division, Multimedia, Supreme court, Revenue stream, University of Pennsylvania, Hunger, BS, ACP, Wharton School of the University of Pennsylvania, Fund, Wendell Pritchett, Online gambling, Financial adviser, Private investigator, Financial services

"We disagree with the decision on multiple grounds and will therefore be moving immediately to appeal", stated Jeremy Kim, General Counsel with NYPPEX.

Key Points: 
  • "We disagree with the decision on multiple grounds and will therefore be moving immediately to appeal", stated Jeremy Kim, General Counsel with NYPPEX.
  • "ACP X, LP (the Fund), a private equity fund advised by ACP Investment Group, takes its regulatory responsibilities extremely seriously.
  • Our appeal submission will point to the many material omissions and errors that render the decision flawed, unreliable and misleading."
  • The ongoing dispute will now move into the appeals process with the New York State Court of Appeals, to reach a final resolution.